Latest Breaking News On - Eiger biopharmaceuticals inc - Page 1 : comparemela.com

AnGes : Notice Regarding the Decision to Sell the ZOKINVY Business of Eiger BioPharmaceuticals, Inc

AnGes : Notice Regarding the Decision to Sell the ZOKINVY Business of Eiger BioPharmaceuticals, Inc
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Eiger zokinvyZydus lifesciences ltdUs bankruptcy courtEiger biopharmaceuticals incSentynl therapeutics incAnges incCompany nameEiger biopharmaceuticalsSentynl therapeuticsZydus lifesciences

StockNews com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)

StockNews com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesEiger biopharmaceuticals company profileEiger biopharmaceuticals incEiger biopharmaceuticalsFree reportGet free reportEiger biopharmaceuticals daily

Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals

/PRNewswire/ Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (Zydus Group), and Eiger.

United statesUnited kingdomGreat britainFrancis collinsZydus lifesciencesSam bernsProgeroid laminopathiesDavid apelianEiger zokinvyZokinvy lonafarnibAudrey gordonSharvil patelGenetics consortiumZydus groupUniversity of washingtonMinistry of health

Head-To-Head Survey: Eiger BioPharmaceuticals (NASDAQ:EIGR) and XOMA (NASDAQ:XOMAP)

Eiger BioPharmaceuticals (NASDAQ:EIGR – Get Free Report) and XOMA (NASDAQ:XOMAP – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Insider and Institutional Ownership 62.5% of Eiger BioPharmaceuticals shares […]

United statesPalo altoAsia pacificEiger biopharmaceuticals incEiger biopharmaceuticalsGet free reportGiven eiger biopharmaceuticalEiger biopharmaceuticals dailyNasdaq eigrStock comparisonStock analysis

StockNews com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)

Investment analysts at StockNews.com started coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Get Free Report) in a research note issued on Thursday. The firm set a “sell” rating on the biotechnology company’s stock. Eiger BioPharmaceuticals Price Performance Eiger BioPharmaceuticals has a 52-week low of $1.10 and a 52-week high of $43.35. The stock has […]

United statesEiger biopharmaceuticals incEiger biopharmaceuticalsGet free reportEiger biopharmaceuticals dailyNasdaq eigrInitiated coverageStocknews com